Renvela is a prescription medication used to control high phosphorus levels in the blood of people with chronic kidney disease (CKD) who are on dialysis. It is approved for adults and children aged 6 and older. When your kidneys can no longer filter phosphorus effectively, this mineral builds up in your bloodstream and can cause serious problems, and Renvela works by trapping phosphorus in your gut before it ever reaches your blood.
Why Phosphorus Control Matters in Kidney Disease
Healthy kidneys filter excess phosphorus out through urine. When kidney function drops far enough to require dialysis, that filtering ability is severely diminished. Phosphorus from food accumulates in the blood, a condition called hyperphosphatemia. Over time, high phosphorus pulls calcium out of your bones and deposits it in blood vessels, heart valves, and soft tissues. This leads to weakened bones, itchy skin, joint pain, and a significantly higher risk of cardiovascular problems.
Dialysis removes some phosphorus, but not enough on its own. Dietary restrictions help, but phosphorus is found in so many foods (dairy, meat, beans, processed foods with phosphate additives) that diet alone rarely keeps levels in a safe range. That’s where phosphate binders like Renvela come in. They’re considered a core part of phosphorus management for most dialysis patients.
How Renvela Works
Renvela contains sevelamer carbonate, a polymer that acts like a sponge for phosphorus inside your digestive tract. It is not absorbed into your bloodstream at all. Instead, it stays in the gut, where it binds to phosphorus from the food you eat through a combination of ionic and hydrogen bonding. The bound phosphorus then passes out of your body in stool, which lowers the amount that gets absorbed into your blood.
One important distinction: Renvela is free of both calcium and metal. Older phosphate binders were calcium-based, which effectively lowered phosphorus but added a large daily calcium load. Some studies suggest that extra calcium can accelerate calcification of blood vessels and heart valves, which is already a major concern for dialysis patients. Sevelamer avoids this issue entirely because it contains no calcium. However, whether this translates into clearly better long-term outcomes is still debated. Several clinical trials, including the Treat-To-Goal and Renagel in New Dialysis studies, suggest sevelamer may slow vascular calcification compared to calcium-based binders, but the data remain mixed. Cleveland Clinic guidelines recommend considering non-calcium binders like Renvela for patients who have complicated diabetes, existing vascular or valve calcification, or persistent inflammation.
Available Forms
Renvela comes in two forms: tablets and a powder for oral suspension. Tablets are swallowed whole with meals. The powder version is mixed with water before drinking and is particularly useful for children or anyone who has difficulty swallowing tablets.
If you’re using the powder, preparation is straightforward but has a few rules. For a 0.4 g or 0.8 g dose, mix the powder into at least 1 ounce (about 2 tablespoons) of water. For a 2.4 g dose, use at least 2 ounces (4 tablespoons). Stir the mixture vigorously. It won’t dissolve completely, so you may need to re-stir right before drinking. You need to drink the entire preparation within 30 minutes. As an alternative, you can mix the powder into a small amount of food or another beverage and consume it immediately as part of your meal.
How and When to Take It
Renvela is taken with meals, typically three times a day. This timing is essential because the medication needs to be present in your digestive tract at the same time as the phosphorus from your food. Taking it between meals or on an empty stomach won’t accomplish much.
Your starting dose depends on your current phosphorus levels, and your doctor will adjust the dose over time based on blood test results. The goal is to bring your serum phosphorus into a target range, which usually requires periodic dose increases or decreases as your diet and dialysis schedule shift. Regular blood work is a normal part of this process.
Potential Side Effects
Because Renvela works entirely within the gastrointestinal tract, the most common side effects are digestive. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are the issues patients report most often. For many people, these are mild and improve as the body adjusts. Taking Renvela with food (as directed) tends to reduce stomach-related complaints.
More serious but rare complications involve bowel obstruction or blockage. Renvela should not be used by anyone who has a bowel obstruction. If you experience severe constipation, bloating, or abdominal pain that doesn’t resolve, that warrants prompt medical attention.
Interactions With Other Medications
Because Renvela binds substances in the gut, it can also bind to other medications you take by mouth, reducing how well they’re absorbed. This is a practical concern for dialysis patients, who often take multiple prescriptions. The general strategy is to take other oral medications either well before or well after Renvela, so the binder doesn’t interfere with their absorption. Your pharmacist or nephrologist can help you map out a timing schedule that keeps everything effective.
Thyroid medications, certain seizure drugs, and some blood pressure medications are among the drugs most commonly flagged for timing separation. If you’re starting Renvela and already take several other prescriptions, it’s worth reviewing the full list with your care team to identify any that need adjusted timing.
How Renvela Compares to Other Phosphate Binders
Phosphate binders fall into a few categories. Calcium-based options (calcium acetate, calcium carbonate) are inexpensive and widely used, but they add to your daily calcium intake at a time when calcium balance is already precarious. Aluminum-based binders are effective but rarely used long-term due to the risk of aluminum accumulation and toxicity. Lanthanum carbonate is another non-calcium option, though it contains a metal.
Renvela occupies a middle ground: it contains no calcium and no metal, making it a good fit for patients at higher cardiovascular risk. The trade-off is cost. Non-calcium binders are generally more expensive than calcium-based alternatives. The choice between binder types often comes down to your individual risk factors, tolerance of side effects, pill burden, and insurance coverage. Some patients end up taking a combination of binders to balance effectiveness, cost, and side effects.